论文部分内容阅读
目的分析局限期原发性食管小细胞癌(PESC)的临床特点及其诊治与预后。方法回顾性分析2004年6月至2012年2月厦门大学附属第一医院收治的20例局限期原发性食管小细胞癌临床资料,并对其治疗手段、生存预后进行分析。结果全组20例患者中位无进展生存(PFS)5.7个月(3.9～7.5个月,95%CI),中位生存(OS)16.1个月(9.3～23.0个月,95%CI)。15例曾接受化学治疗(术前新辅助化疗、放疗中同步化疗或术后辅助化疗)患者的PFS显著高于未接受化学治疗的患者(9.9月vs 3.7月,P=0.02),但化疗与否并不影响总生存。结论食管小细胞癌目前尚无标准治疗模式。但包含了化学治疗的综合治疗可能是一种值得进一步探讨和推荐的治疗方式。
Objective To analyze the clinical features, diagnosis and prognosis of primary esophageal small cell carcinoma (PESC). Methods The clinical data of 20 patients with localized primary esophageal small cell carcinoma admitted to the First Affiliated Hospital of Xiamen University from June 2004 to February 2012 were analyzed retrospectively. The treatment and prognosis were analyzed. Results The median progression-free survival (PFS) was 5.7 months (3.9-7.5 months, 95% CI) and median OS was 16.1 months (9.3-23.0 months, 95% CI) in all 20 patients. PFS was significantly higher in 15 patients who had undergone chemotherapy (preoperative neoadjuvant chemotherapy, concurrent chemoradiation, or postoperative adjuvant chemotherapy) compared with those who did not receive chemotherapy (September.9 vs.3.7, P = 0.02), but chemotherapy and No does not affect the overall survival. Conclusion There is no standard treatment for esophageal small cell carcinoma. However, a combination therapy that includes chemotherapy may be a treatment that deserves further exploration and recommendation.